Research progress on therapy-related hematological neoplasms in solid tumors
10.12354/j.issn.1000-8179.2024.20240562
- VernacularTitle:实体瘤治疗相关血液肿瘤的研究进展
- Author:
Sun BIWEN
1
;
Zheng HONG
;
Wang YAFEI
;
Tian CHEN
Author Information
1. 天津医科大学肿瘤医院血液科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)
- Keywords:
malignant solid tumors;
therapy-related hematological neoplasms;
therapy-related myeloid neoplasm(t-MN)
- From:
Chinese Journal of Clinical Oncology
2024;51(10):534-537
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the number of diagnosed therapy-related hematological neoplasms has increased.Compared to primary hemato-logical neoplasms,therapy-related hematological neoplasms have a poorer prognosis and are a serious complication following the treat-ment of solid tumors.Clonal hematopoiesis of indeterminate potential(CHIP)is considered a relevant factor in the pathogenesis of therapy-related myeloid neoplasms(t-MNs),leading to an increased risk of t-MN by promoting driver gene mutations.The pathogenesis of therapy-related hematological neoplasms primarily involves alkylating agents,topoisomerase inhibitors,platinum agents,poly ADP-ribose poly-merase(PARP)inhibitors,and radiotherapy.Currently,allogeneic stem cell transplantation remains the most effective therapeutic option.This review analyzes advances in the epidemiology,pathogenesis,related drugs,prognosis,and treatment of therapy-related hematological neoplasms.
